Literature DB >> 28572256

Mutational Signatures in Breast Cancer: The Problem at the DNA Level.

Serena Nik-Zainal1,2, Sandro Morganella3.   

Abstract

A breast cancer genome is a record of the historic mutagenic activity that has occurred throughout the development of the tumor. Indeed, every mutation may be informative. Although driver mutations were the main focus of cancer research for a long time, passenger mutational signatures, the imprints of DNA damage and DNA repair processes that have been operative during tumorigenesis, are also biologically illuminating. This review is a chronicle of how the concept of mutational signatures arose and brings the reader up-to-date on this field, particularly in breast cancer. Mutational signatures have now been advanced to include mutational processes that involve rearrangements, and novel cancer biological insights have been gained through studying these in great detail. Furthermore, there are efforts to take this field into the clinical sphere. If validated, mutational signatures could thus form an additional weapon in the arsenal of cancer precision diagnostics and therapeutic stratification in the modern war against cancer. Clin Cancer Res; 23(11); 2617-29. ©2017 AACRSee all articles in this CCR Focus section, "Breast Cancer Research: From Base Pairs to Populations." ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28572256      PMCID: PMC5458139          DOI: 10.1158/1078-0432.CCR-16-2810

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  73 in total

1.  BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.

Authors:  Rachel Litman; Min Peng; Zhe Jin; Fan Zhang; Junran Zhang; Simon Powell; Paul R Andreassen; Sharon B Cantor
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

2.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Authors:  Helen Davies; Dominik Glodzik; Sandro Morganella; Lucy R Yates; Johan Staaf; Xueqing Zou; Manasa Ramakrishna; Sancha Martin; Sandrine Boyault; Anieta M Sieuwerts; Peter T Simpson; Tari A King; Keiran Raine; Jorunn E Eyfjord; Gu Kong; Åke Borg; Ewan Birney; Hendrik G Stunnenberg; Marc J van de Vijver; Anne-Lise Børresen-Dale; John W M Martens; Paul N Span; Sunil R Lakhani; Anne Vincent-Salomon; Christos Sotiriou; Andrew Tutt; Alastair M Thompson; Steven Van Laere; Andrea L Richardson; Alain Viari; Peter J Campbell; Michael R Stratton; Serena Nik-Zainal
Journal:  Nat Med       Date:  2017-03-13       Impact factor: 53.440

Review 3.  Somatic TP53 Mutations in the Era of Genome Sequencing.

Authors:  Pierre Hainaut; Gerd P Pfeifer
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

4.  Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair.

Authors:  Nicholas J Haradhvala; Paz Polak; Petar Stojanov; Kyle R Covington; Eve Shinbrot; Julian M Hess; Esther Rheinbay; Jaegil Kim; Yosef E Maruvka; Lior Z Braunstein; Atanas Kamburov; Philip C Hanawalt; David A Wheeler; Amnon Koren; Michael S Lawrence; Gad Getz
Journal:  Cell       Date:  2016-01-21       Impact factor: 41.582

Review 5.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

6.  EMu: probabilistic inference of mutational processes and their localization in the cancer genome.

Authors:  Andrej Fischer; Christopher J R Illingworth; Peter J Campbell; Ville Mustonen
Journal:  Genome Biol       Date:  2013-04-29       Impact factor: 13.583

7.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Alex Murison; Eileen M Boyle; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; Lorenzo Melchor; Charlotte Pawlyn; Martin F Kaiser; David C Johnson; Ya-Wei Qiang; John R Jones; David A Cairns; Walter M Gregory; Roger G Owen; Gordon Cook; Mark T Drayson; Graham H Jackson; Faith E Davies; Gareth J Morgan
Journal:  Nat Commun       Date:  2015-04-23       Impact factor: 14.919

8.  Cell-of-origin chromatin organization shapes the mutational landscape of cancer.

Authors:  Paz Polak; Rosa Karlić; Amnon Koren; Robert Thurman; Richard Sandstrom; Michael Lawrence; Alex Reynolds; Eric Rynes; Kristian Vlahoviček; John A Stamatoyannopoulos; Shamil R Sunyaev
Journal:  Nature       Date:  2015-02-19       Impact factor: 49.962

9.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants.

Authors:  Julian S Gehring; Bernd Fischer; Michael Lawrence; Wolfgang Huber
Journal:  Bioinformatics       Date:  2015-07-10       Impact factor: 6.937

10.  A Simple Model-Based Approach to Inferring and Visualizing Cancer Mutation Signatures.

Authors:  Yuichi Shiraishi; Georg Tremmel; Satoru Miyano; Matthew Stephens
Journal:  PLoS Genet       Date:  2015-12-02       Impact factor: 5.917

View more
  49 in total

1.  Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.

Authors:  Francisco Beca; Simon S K Lee; Fresia Pareja; Arnaud Da Cruz Paula; Pier Selenica; Lorenzo Ferrando; Rodrigo Gularte-Mérida; Hannah Y Wen; Hong Zhang; Elena Guerini-Rocco; Emad A Rakha; Britta Weigelt; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2019-10-13       Impact factor: 5.087

2.  APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status.

Authors:  Krizia-Ivana Udquim; Clara Zettelmeyer; A Rouf Banday; Seraph Han-Yin Lin; Ludmila Prokunina-Olsson
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

3.  The molecular genetic make-up of male breast cancer.

Authors:  Cathy B Moelans; Joep de Ligt; Petra van der Groep; Pjotr Prins; Nicolle J M Besselink; Marlous Hoogstraat; Natalie D Ter Hoeve; Miangela M Lacle; Robert Kornegoor; Carmen C van der Pol; Wendy W J de Leng; Ellis Barbé; Bert van der Vegt; John Martens; Peter Bult; Vincent T H B M Smit; Marco J Koudijs; Isaac J Nijman; Emile E Voest; Pier Selenica; Britta Weigelt; Jorge S Reis-Filho; Elsken van der Wall; Edwin Cuppen; Paul J van Diest
Journal:  Endocr Relat Cancer       Date:  2019-10       Impact factor: 5.678

4.  Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers.

Authors:  Zhishan Chen; Wanqing Wen; Alicia Beeghly-Fadiel; Xiao-Ou Shu; Virginia Díez-Obrero; Jirong Long; Jiandong Bao; Jing Wang; Qi Liu; Qiuyin Cai; Victor Moreno; Wei Zheng; Xingyi Guo
Journal:  Am J Hum Genet       Date:  2019-08-08       Impact factor: 11.025

5.  Immunotherapy for Breast Cancer: What Are We Missing?

Authors:  Robert H Vonderheide; Susan M Domchek; Amy S Clark
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

6.  Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.

Authors:  Katherine E Reeder-Hayes; Benjamin O Anderson
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

7.  Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?

Authors:  Ann H Partridge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

8.  Kindlin-2 promotes Src-mediated tyrosine phosphorylation of androgen receptor and contributes to breast cancer progression.

Authors:  Luyao Ma; Yeteng Tian; Tao Qian; Wenjun Li; Chengmin Liu; Bizhu Chu; Qian Kong; Renwei Cai; Panzhu Bai; Lisha Ma; Yi Deng; Ruijun Tian; Chuanyue Wu; Ying Sun
Journal:  Cell Death Dis       Date:  2022-05-20       Impact factor: 9.685

9.  The Genomic Landscape of Mucinous Breast Cancer.

Authors:  Fresia Pareja; Ju Youn Lee; David N Brown; Salvatore Piscuoglio; Rodrigo Gularte-Mérida; Pier Selenica; Arnaud Da Cruz Paula; Sasi Arunachalam; Rahul Kumar; Felipe C Geyer; Catarina Silveira; Edaise M da Silva; Anqi Li; Caterina Marchiò; Charlotte K Y Ng; Odette Mariani; Laetitia Fuhrmann; Hannah Y Wen; Larry Norton; Anne Vincent-Salomon; Edi Brogi; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

10.  The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

Authors:  Ben O'Leary; Rosalind J Cutts; Yuan Liu; Sarah Hrebien; Xin Huang; Kerry Fenwick; Fabrice André; Sibylle Loibl; Sherene Loi; Isaac Garcia-Murillas; Massimo Cristofanilli; Cynthia Huang Bartlett; Nicholas C Turner
Journal:  Cancer Discov       Date:  2018-09-11       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.